Acute and Chronic Neurotoxicity in Novel Mouse Models of Acute Intoxication with Diverse Chemical Threat Agents
Skip to main content
eScholarship
Open Access Publications from the University of California

UC Davis

UC Davis Electronic Theses and Dissertations bannerUC Davis

Acute and Chronic Neurotoxicity in Novel Mouse Models of Acute Intoxication with Diverse Chemical Threat Agents

Abstract

Organophosphate (OP) cholinesterase inhibitors and GABA receptor antagonists represent mechanistically diverse classes of chemicals that can cause seizures and death following acute intoxication at relatively low doses. OPs inhibit acetylcholinesterase (AChE), which results in the over accumulation of acetylcholine (ACh) in the nervous system. Rapid inhibition of > 60-80% of brain AChE triggers seizures that rapidly progress to life-threatening status epilepticus (SE). GABA receptor antagonists, exemplified by tetramethylenedisulfotetramine (TETS), induce seizures and death by reducing the inhibitory tone in the nervous system, which results in neuronal hyperexcitability. The standard first-line therapy for the treatment of TETS- or OP-induced SE, high-dose benzodiazepines, are effective at terminating seizure behavior and reducing mortality if administered within minutes after exposure. However, even with timely treatment, benzodiazepines often fail to adequately protect against subsequent brain damage and neurologic deficits. Preclinical rodent models are essential to elucidating the cellular and molecular mechanisms driving acute seizurogenic events and the spatiotemporal progression of brain damage following SE. The major objective of this dissertation was to characterize acute and chronic neurotoxic outcomes in novel mouse models of TETS- and OP-induced SE to gain a better understanding of the pathogenic mechanisms contributing to SE and the consequential neuropathology. In Chapter 2, in vivo imaging is used to compare the spatiotemporal progression of neuropathology after TETS-SE in two different mouse strains commonly used to study chemical-induced SE. The findings in this study demonstrate that the extent of brain damage observed in the mouse brain after TETS-induced SE varies according to strain and the duration of SE. Chapter 3 focuses on the development and characterization of a mouse model of acute intoxication with diisopropylfluorophosphate (DFP). Specifically, this chapter describes the spatiotemporal progression of AChE inhibition, neuropathology, and behavioral deficits up to 28 days post-exposure. The findings in this chapter demonstrate that this mouse model replicates many of the outcomes observed in rats and humans acutely intoxicated with OPs, suggesting the feasibility of using this model for mechanistic studies and therapeutic screening. The mouse model of acute DFP intoxication was leveraged in Chapter 4 to investigate the role of nicotinic cholinergic receptors (nAChR) in the initiation and propagation of OP-induced SE. The findings described in Chapter 4 identify a role for α4-containing nAChR in the initiation and/or progression of seizures following acute OP intoxication, and support further investigation of nicotinic antagonists as prophylactics for OP-induced SE. The studies presented in this dissertation support the use of mouse models to investigate the mechanisms contributing to the initiation and consequences of SE caused by chemical threat agents. The findings of this work have important mechanistic and therapeutic implications regarding the pathophysiology and treatment of chemical-induced SE. The observation that genetic background and duration of SE influence the neuropathologic consequences of TETS-SE suggests that humans who do not respond to antiseizure medication after acute TETS intoxication are at increased risk for brain injury, and this susceptibility may vary genetically. The observation that nicotinic receptors play a necessary role in the initiation of OP-induced SE highlights a novel therapeutic target, and supports the strategy of using a nicotinic antagonist as a preventative antidote against OP-induced seizures.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View